Protara Therapeutics

Protara Therapeutics Receives FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Lymphatic Malformations

3 weeks ago talkbio0Tagged Breakthrough Therapy, Fast Track, Lymphatic Abnormalities, Lyophilized Inactivated Group A Streptococcus TARA-002, Pediatric brand name, Protara Therapeutics, United States Food and Drug Administration

Protara Therapeutics; TARA-002; FDA; Breakthrough Therapy; Fast Track; Lymphatic Malformations; Pediatric

Protara Therapeutics Sees Significant Stock Surge Following Positive Phase 2 Trial Results for TARA-002 in Bladder Cancer

1 year ago talkbio0Tagged Lyophilized Inactivated Group A Streptococcus TARA-002, Malignant neoplasm of urinary bladder, Non-Muscle Invasive Bladder Neoplasms, Phase 2 trial, Protara Therapeutics, safety profile

Protara Therapeutics, TARA-002, bladder cancer, NMIBC, Phase 2 trial, complete response rate, safety profile

Breakthroughs in Bladder Cancer Treatment: Protara and CG Oncology Report Encouraging Outcomes

1 year ago talkbio0Tagged Carcinoma of urinary bladder, invasive, Cell Therapy, centigram, Cretostimogene Grenadenorepvec, Lyophilized Inactivated Group A Streptococcus TARA-002, Malignant Neoplasms, Neoplasms, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Oncolytic Immunotherapy, Protara Therapeutics, Urinary Bladder

Bladder Cancer Treatment, Protara Therapeutics, CG Oncology, TARA-002, Cretostimogene Grenadenorepvec, Non-Muscle Invasive Bladder Cancer (NMIBC), Oncolytic Immunotherapy, Cell Therapy

Protara’s TARA-002 Cell Therapy Shows Exceptional Promise in Treating Non-Muscle Invasive Bladder Cancer

1 year ago talkbio0Tagged BCG-Naïve, BCG-Unresponsive, Carcinoma of urinary bladder, invasive, Cell Therapy, Clinical Trials, Lyophilized Inactivated Group A Streptococcus TARA-002, Non-Muscle, Non-Muscle Invasive Bladder Neoplasms, Phase 2, Protara Therapeutics

Protara Therapeutics, TARA-002, Non-Muscle Invasive Bladder Cancer (NMIBC), Phase 2 ADVANCED-2 trial, Cell therapy, BCG-Unresponsive, BCG-Naïve